Filter

61 - 70 of 78 Results

  • Medicaid’s Most Costly Outpatient Drugs

    Issue Brief

    Using Medicaid State Drug Utilization Data, this brief presents the 50 most costly drugs before rebates used by the Medicaid program over the January 2014 through June 2015 period. It then examines reasons why these drugs are so costly; explores case studies on opioids, hepatitis C drugs, and the drug Abilify; and considers policy implications.

  • Analysis Finds Specialty Drugs Rank High Among Medicaid’s Most Costly Outpatient Drugs

    News Release

    Costly specialty drugs, such as those used to treat Hepatitis C and HIV, are among the most costly medications in state Medicaid programs, chiefly because of their high prices for a course of treatment, according to a new Kaiser Family Foundation analysis of Medicaid’s most costly outpatient drugs. Abilify, an antiphsychotic used in the treatment of schizophrenia and bipolar disorder, was the most costly drug in state Medicaid programs overall in the new analysis, which…

  • States Focus on Quality and Outcomes Amid Waiver Changes: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2018 and 2019

    Report

    This report provides an in-depth examination of the changes taking place in Medicaid programs across the country. Report findings are drawn from the annual budget survey of Medicaid officials in all 50 states and the District of Columbia. This report examines the reforms, policy changes, and initiatives that occurred in FY 2018 and those adopted for implementation for FY 2019 (which began for most states on July 1, 2018). Key areas covered include changes in…

  • Addressing the Opioid Crisis: Medication-Assisted Treatment at Health Care for the Homeless Programs

    Issue Brief

    Health Care for the Homeless (HCH) programs, a subset of community health centers, play a significant role in addressing the opioid epidemic by providing medication-assisted treatment (MAT). MAT, which combines one of three medications (methadone, buprenorphine, or naltrexone) with behavioral therapies, is the standard of care for opioid use disorder (OUD). This brief presents findings from an analysis of health center data on the provision of buprenorphine-based MAT, as well as interviews with providers and…

  • Opioid Use Disorder among Medicaid Enrollees: Snapshot of the Epidemic and State Responses

    Issue Brief

    As the largest payer of substance use disorder services in the United States, Medicaid plays a central role in state efforts to address the opioid epidemic. In addition to increasing access to addiction treatment services through the expansion of Medicaid under the Affordable Care Act (ACA), states are expanding Medicaid addiction treatment services, increasing provider reimbursements, restricting opioid prescribing, and implementing delivery system reforms to improve the quality of treatment services. While many states have…

  • The Opioid Epidemic and Medicaid’s Role in Facilitating Access to Treatment

    Issue Brief

    This brief describes nonelderly adults with opioid use disorder, including their demographic characteristics and insurance status, and compares utilization of treatment services among those with Medicaid to those with other types of coverage. It also describes Medicaid financing for opioid treatment and the ways in which Medicaid promotes access to treatment for enrollees with OUD.

  • Governors’ Proposed Budgets for FY 2019: Focus on Medicaid and Other Health Priorities

    Issue Brief

    This issue brief provides Medicaid highlights from governors’ proposed budgets for state fiscal year (FY) 2019 (July 1, 2018 through June 30, 2019 in most states). Proposed budgets reflect the priorities of the governor and are often blueprints for the legislature to consider. In total, we reviewed 39 proposed state budgets and text from 46 state of the state speeches. This review revealed that while state revenue collections improved in 2017 compared to 2016, considerable…